We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-4.45%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.08B
AUM Growth
+$322M
Cap. Flow
+$648M
Cap. Flow %
21%
Top 10 Hldgs %
37.4%
Holding
321
New
89
Increased
78
Reduced
45
Closed
96

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32M
2
CCCC icon
C4 Therapeutics
CCCC
+$14.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.1M
4
AMRS
Amyris Inc.
AMRS
+$11M
5
TECH icon
Bio-Techne
TECH
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$14.1M
2
DXCM icon
DexCom
DXCM
+$14.1M
3
ICUI icon
ICU Medical
ICUI
+$14M
4
LIVN icon
LivaNova
LIVN
+$12.2M
5
OLPX
Olaplex Holdings
OLPX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 24.06%
2 Materials 0.35%
3 Industrials 0.17%
4 Consumer Discretionary 0.07%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXL icon
151
CALL
Anavex Life Sciences
AVXL
$316M
$2.46M 0.08%
+200,000
New +$2.46M
LHDX
152
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$2.45M 0.08%
687,213
-478,017
-41% -$2.35M
NKTR icon
153
CALL
Nektar Therapeutics
NKTR
$2.57B
$2.34M 0.08%
28,993
-5,994
-17% -$887K
NNOX icon
154
PUT
Nano X Imaging
NNOX
$71M
$2.17M 0.07%
+200,000
New +$2.14M
PTON icon
155
Peloton Interactive
PTON
$2.38B
$2.11M 0.07%
+80,000
New +$2.29M
LYRA
156
DELISTED
LYRA THERAPEUTICS INC
LYRA
$2.09M 0.07%
10,411
+66
+0.6% +$14.5K
ADPT icon
157
Adaptive Biotechnologies
ADPT
$4.02B
$2.08M 0.07%
+150,000
New +$2.36M
SRPT icon
158
Sarepta Therapeutics
SRPT
$1.94B
$2.02M 0.07%
+25,850
New +$1.98M
ALNY icon
159
CALL
Alnylam Pharmaceuticals
ALNY
$30B
$2.01M 0.07%
+12,300
New +$1.87M
AZN icon
160
AstraZeneca
AZN
$246B
$1.99M 0.06%
+15,000
New +$1.8M
VRDN icon
161
Viridian Therapeutics
VRDN
$2.59B
$1.95M 0.06%
105,460
+600
+0.6% +$11.5K
LQDA icon
162
Liquidia Corp
LQDA
$7.01B
$1.81M 0.06%
251,604
+200,200
+389% +$1.26M
AUPH icon
163
CALL
Aurinia Pharmaceuticals
AUPH
$2.06B
$1.77M 0.06%
143,000
+900
+0.6% +$13.9K
UBX
164
DELISTED
Unity Biotechnology
UBX
$1.77M 0.06%
+157,814
New +$1.77M
MRUS
165
DELISTED
Merus
MRUS
$1.76M 0.06%
66,547
+7,887
+13% +$211K
SDGR icon
166
Schrodinger
SDGR
$1.39B
$1.71M 0.06%
+50,000
New +$1.52M
TXG icon
167
10x Genomics
TXG
$7.52B
$1.69M 0.05%
22,257
-39,700
-64% -$3.47M
RUBY
168
CALL
DELISTED
Rubius Therapeutics, Inc
RUBY
$1.65M 0.05%
+300,000
New +$1.91M
DALS
169
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$1.6M 0.05%
164,834
– –
RCUS icon
170
CALL
Arcus Biosciences
RCUS
$3.69B
$1.58M 0.05%
+50,000
New +$1.68M
PTGX icon
171
Protagonist Therapeutics
PTGX
$9.84B
$1.55M 0.05%
+65,371
New +$1.84M
TCDA
172
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.49M 0.05%
+180,816
New +$1.64M
KDNY
173
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.39M 0.05%
85,236
-5,005
-6% -$68K
PHAT icon
174
Phathom Pharmaceuticals
PHAT
$742M
$1.39M 0.05%
102,328
+600
+0.6% +$9.69K
MAPS
175
DELISTED
WM TECHNOLOGY INC A
MAPS
$1.39M 0.05%
+178,000
New +$1.01M
5 6
7
8 9

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Pura Vida Investments held 321 positions worth $3.08B, up 12% from $2.76B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $648M of net new capital in Q1 2022, opening 89 new positions and adding to 78 existing holdings. Its largest new stake was Biogen: 147,135 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 30% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was ICU Medical, an estimated $14M trimmed.

  • Pura Vida Investments's largest Q1 2022 buy was Biogen: 147,135 shares worth $31M.
  • Pura Vida Investments added most to C4 Therapeutics in Q1 2022, an estimated $14.5M increase.
  • Pura Vida Investments's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $14M.
  • Pura Vida Investments fully exited Natera in Q1 2022, selling an estimated $14.1M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $3.08B portfolio in Q1 2022.
  • Pura Vida Investments opened 89 new positions and closed 96 in Q1 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $3.08B.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.